Lilly Oncology Medical's banner
Lilly Oncology Medical's profile picture

Lilly Oncology Medical

@LillyOncMed • 6,688 subscribers

Dedicated to communicating the latest science & disease state education from Lilly Oncology. Intended for U.S. HCPs. Community Guidelines: https://t.co/1q8vAe63mK

Shorts

CURRENTLY ENROLLING: A phase 2 clinical trial evaluating a CDK 4/6 inhibitor + temozolomide versus temozolomide monotherapy in children and young adults with newly diagnosed high-grade Glioma. HCPs - Find trial and enrollment info here:

CURRENTLY ENROLLING: A phase 2 clinical trial evaluating a CDK 4/6 inhibitor + temozolomide versus temozolomide monotherapy in children and young adults with newly diagnosed high-grade Glioma. HCPs - Find trial and enrollment info here:

1,217,031 görüntüleme

KRAS G12C is distinct from other oncogenic drivers, meaning patients with KRAS G12C–mutant NSCLC need a different approach. Explore more about this unique disease profile on our website.

KRAS G12C is distinct from other oncogenic drivers, meaning patients with KRAS G12C–mutant NSCLC need a different approach. Explore more about this unique disease profile on our website.

198,071 görüntüleme

Videos

LIVE
1.2k

Anya Rossi

sweetdream.ai

SweetDream.aiSponsored•Livecam
Streaming Now

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

HD live stream
Exclusive private shows
1.2k viewers online

Free preview available • Premium content

Currently enrolling: FiREBOLT, a Phase 1 clinical trial evaluating a FAP-targeted radioligand therapy for patients with FAP+ solid tumors. Click below to explore study details & participation considerations⬇️
0:30
LillyOncMed's profile picture

Currently enrolling: FiREBOLT, a Phase 1 clinical trial evaluating a FAP-targeted radioligand therapy for patients with FAP+ solid tumors. Click below to explore study details & participation considerations⬇️

Lilly Oncology Medical

3,041,143 görüntüleme • 2 ay önce

FRAmework-01 | Now Enrolling A Ph3 trial evaluating a FRα-targeting ADC in patients with ovarian cancer. Key details: - Enrolling PSOC and PROC - All FRα expression levels - Allows prior mirvetuximab 👇 Click below for trial and enrollment details
1:45
LillyOncMed's profile picture

FRAmework-01 | Now Enrolling A Ph3 trial evaluating a FRα-targeting ADC in patients with ovarian cancer. Key details: - Enrolling PSOC and PROC - All FRα expression levels - Allows prior mirvetuximab 👇 Click below for trial and enrollment details

Lilly Oncology Medical

2,675,562 görüntüleme • 7 ay önce

KRAS G12C inhibitors can potentially be synergistic or additive when combined with immunotherapy or chemotherapy based on preclinical data. Ongoing Phase 3 trials are investigating these strategies further. Click the image below to learn more⬇️
0:20
LillyOncMed's profile picture

KRAS G12C inhibitors can potentially be synergistic or additive when combined with immunotherapy or chemotherapy based on preclinical data. Ongoing Phase 3 trials are investigating these strategies further. Click the image below to learn more⬇️

Lilly Oncology Medical

548,537 görüntüleme • 1 ay önce

Patients with HR+, HER2- metastatic breast cancer (MBC) harboring ≥1 poor prognostic factor have significantly shorter real-world progression free survival and overall survival compared to those with no prognostic factors. 🩺 Click the link below to learn more
1:12
LillyOncMed's profile picture

Patients with HR+, HER2- metastatic breast cancer (MBC) harboring ≥1 poor prognostic factor have significantly shorter real-world progression free survival and overall survival compared to those with no prognostic factors. 🩺 Click the link below to learn more

Lilly Oncology Medical

1,014,069 görüntüleme • 1 yıl önce

~3 in 10 patients with node-positive, high-risk, HR+, HER2- #EarlyBreastCancer (EBC) may experience recurrence within 5 years. It is vital to identify these patients and intensify their treatment. Learn more here👉: #BreastCancerResearch #bcsm #ESMO2024
0:47
LillyOncMed's profile picture

~3 in 10 patients with node-positive, high-risk, HR+, HER2- #EarlyBreastCancer (EBC) may experience recurrence within 5 years. It is vital to identify these patients and intensify their treatment. Learn more here👉: #BreastCancerResearch #bcsm #ESMO2024

Lilly Oncology Medical

509,920 görüntüleme • 2 yıl önce

Two CDK4/6 inhibitors are approved for select patients w/ high-risk HR+, HER2-#EarlyBreastCancer. Understanding the design of CDK4/6i adjuvant trials can help HCPs optimize treatment plans. #BCSM 📚Explore our library of EBC educational resources here:
1:24
LillyOncMed's profile picture

Two CDK4/6 inhibitors are approved for select patients w/ high-risk HR+, HER2-#EarlyBreastCancer. Understanding the design of CDK4/6i adjuvant trials can help HCPs optimize treatment plans. #BCSM 📚Explore our library of EBC educational resources here:

Lilly Oncology Medical

56,675 görüntüleme • 1 yıl önce

Daha fazla içerik yok.